164265-01-4 Usage
General Description
6-CHLORO-CHROMAN-3-CARBOXYLIC ACID, also known as 3-carboxy-6-chlorochroman, is a chemical compound with the molecular formula C9H7ClO3. It is a chlorinated derivative of chroman-3-carboxylic acid, and is commonly used in the pharmaceutical industry as a starting material in the synthesis of various pharmaceutical drugs. 6-CHLORO-CHROMAN-3-CARBOXYLIC ACID has shown potential for various biological activities, including anticancer, anti-inflammatory, and antioxidant properties. It is also used in the production of dyes, pigments, and other chemical intermediates. 6-CHLORO-CHROMAN-3-CARBOXYLIC ACID is typically synthesized through a series of chemical reactions involving the chlorination of chroman-3-carboxylic acid. It is important to handle this compound with care, as it may be harmful if ingested, inhaled, or in contact with skin.
Check Digit Verification of cas no
The CAS Registry Mumber 164265-01-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,4,2,6 and 5 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 164265-01:
(8*1)+(7*6)+(6*4)+(5*2)+(4*6)+(3*5)+(2*0)+(1*1)=124
124 % 10 = 4
So 164265-01-4 is a valid CAS Registry Number.
164265-01-4Relevant articles and documents
6-Chloro-2,3-Dihydro-4H-1-Benzopyran Carboxylic Acids: Synthesis, Optical Resolution and Absolute Configuration
Loiodice, Fulvio,Longo, Antonio,Bianco, Pasquale,Tortorella, Vincenzo
, p. 1001 - 1012 (1995)
6-Chloro-2,3-dihydro-4H-1-benzopyran-2-carboxylic acid, a rigid analogue of clofibric acid, the active metabolite of the antilipidemic drug clofibrate, has been prepared together with two isomers, 6-chloro-2,3-dihydro-4H-1-benzopyran-3- and 4-carboxylic a
Chroman-3-amides as potent Rho kinase inhibitors
Chen, Yen Ting,Bannister, Thomas D.,Weiser, Amiee,Griffin, Evelyn,Lin, Li,Ruiz, Claudia,Cameron, Michael D.,Schuerer, Stephan,Duckett, Derek,Schroeter, Thomas,LoGrasso, Philip,Feng, Yangbo
scheme or table, p. 6406 - 6409 (2009/10/01)
Inhibition of Rho kinase (ROCK) is an attractive strategy for the treatment of diseases such as hypertension, glaucoma, and cancer. Here we report chroman-3-amides as highly potent ROCK inhibitors with sufficient kinase selectivity, excellent cell activit
